Latest Insider Transactions at Biogen Inc. (BIIB)
This section provides a real-time view of insider transactions for Biogen Inc. (BIIB). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of BIOGEN INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of BIOGEN INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 03
2024
|
Priya Singhal Head of Development |
SELL
Open market or private sale
|
Direct |
431
-7.5%
|
$87,924
$204.22 P/Share
|
|
Aug 30
2024
|
Priya Singhal Head of Development |
SELL
Payment of exercise price or tax liability
|
Direct |
807
-12.31%
|
$164,628
$204.76 P/Share
|
|
Aug 30
2024
|
Priya Singhal Head of Development |
BUY
Exercise of conversion of derivative security
|
Direct |
1,668
+20.29%
|
-
|
|
Jun 21
2024
|
Jesus B Mantas Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,340
+15.35%
|
-
|
|
Jun 21
2024
|
Stephen A Sherwin Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,340
+6.26%
|
-
|
|
Jun 21
2024
|
Monish D Patolawala Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,340
+50.0%
|
-
|
|
Jun 21
2024
|
Susan Langer Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,340
+32.69%
|
-
|
|
Jun 21
2024
|
Eric K Rowinsky Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,340
+5.75%
|
-
|
|
Jun 21
2024
|
Maria C Freire Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,340
+23.16%
|
-
|
|
Jun 21
2024
|
William A Hawkins Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,340
+17.11%
|
-
|
|
Jun 21
2024
|
Caroline Dorsa Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,785
+6.29%
|
-
|
|
May 01
2024
|
Adam Keeney Head of Corporate Development |
SELL
Payment of exercise price or tax liability
|
Direct |
276
-29.42%
|
$59,616
$216.13 P/Share
|
|
May 01
2024
|
Adam Keeney Head of Corporate Development |
BUY
Exercise of conversion of derivative security
|
Direct |
938
+50.0%
|
-
|
|
Apr 02
2024
|
Priya Singhal Head of Development |
SELL
Open market or private sale
|
Direct |
93
-1.87%
|
$19,809
$213.09 P/Share
|
|
Apr 01
2024
|
Nicole Murphy Head of Pharm Ops and Tech |
SELL
Payment of exercise price or tax liability
|
Direct |
117
-1.2%
|
$25,038
$214.83 P/Share
|
|
Apr 01
2024
|
Nicole Murphy Head of Pharm Ops and Tech |
BUY
Exercise of conversion of derivative security
|
Direct |
240
+2.4%
|
-
|
|
Feb 22
2024
|
Priya Singhal Head of Development |
SELL
Open market or private sale
|
Direct |
262
-5.09%
|
$57,902
$221.23 P/Share
|
|
Feb 16
2024
|
Susan H Alexander EVP Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,437
-2.32%
|
$533,703
$219.08 P/Share
|
|
Feb 16
2024
|
Susan H Alexander EVP Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,037
+4.55%
|
-
|
|
Feb 16
2024
|
Ginger Gregory EVP, Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
2,264
-7.9%
|
$495,816
$219.08 P/Share
|
|
Feb 16
2024
|
Ginger Gregory EVP, Human Resources |
BUY
Exercise of conversion of derivative security
|
Direct |
4,704
+13.88%
|
-
|
|
Feb 16
2024
|
Michael R Mcdonnell EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,438
-8.33%
|
$752,922
$219.08 P/Share
|
|
Feb 16
2024
|
Michael R Mcdonnell EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,720
+13.79%
|
-
|
|
Feb 16
2024
|
Robin Kramer Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
396
-3.17%
|
$86,724
$219.08 P/Share
|
|
Feb 16
2024
|
Robin Kramer Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,345
+9.61%
|
-
|
|
Feb 16
2024
|
Rachid Izzar Head of Global Product Strat. |
SELL
Payment of exercise price or tax liability
|
Direct |
952
-4.76%
|
$208,488
$219.08 P/Share
|
|
Feb 16
2024
|
Rachid Izzar Head of Global Product Strat. |
BUY
Exercise of conversion of derivative security
|
Direct |
2,017
+9.06%
|
-
|
|
Feb 16
2024
|
Priya Singhal Head of Development |
SELL
Open market or private sale
|
Direct |
108
-2.05%
|
$23,868
$221.49 P/Share
|
|
Feb 16
2024
|
Priya Singhal Head of Development |
SELL
Payment of exercise price or tax liability
|
Direct |
468
-4.36%
|
$102,492
$219.08 P/Share
|
|
Feb 16
2024
|
Priya Singhal Head of Development |
BUY
Exercise of conversion of derivative security
|
Direct |
1,208
+10.0%
|
-
|
|
Feb 16
2024
|
Nicole Murphy Head of Pharm Ops and Tech |
SELL
Payment of exercise price or tax liability
|
Direct |
610
-3.17%
|
$133,590
$219.08 P/Share
|
|
Feb 16
2024
|
Nicole Murphy Head of Pharm Ops and Tech |
BUY
Exercise of conversion of derivative security
|
Direct |
1,260
+6.1%
|
-
|
|
Feb 15
2024
|
Eric K Rowinsky Director |
BUY
Open market or private purchase
|
Direct |
455
+2.16%
|
$101,010
$222.54 P/Share
|
|
Feb 12
2024
|
Priya Singhal Head of Development |
SELL
Open market or private sale
|
Direct |
419
-8.49%
|
$100,141
$239.45 P/Share
|
|
Feb 09
2024
|
Ginger Gregory EVP, Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
634
-5.38%
|
$152,160
$240.98 P/Share
|
|
Feb 09
2024
|
Ginger Gregory EVP, Human Resources |
BUY
Exercise of conversion of derivative security
|
Direct |
2,158
+15.49%
|
-
|
|
Feb 09
2024
|
Priya Singhal Head of Development |
SELL
Payment of exercise price or tax liability
|
Direct |
374
-7.04%
|
$89,760
$240.98 P/Share
|
|
Feb 09
2024
|
Priya Singhal Head of Development |
BUY
Exercise of conversion of derivative security
|
Direct |
1,212
+18.59%
|
-
|
|
Feb 09
2024
|
Rachid Izzar Head of Global Product Strat. |
SELL
Payment of exercise price or tax liability
|
Direct |
445
-4.9%
|
$106,800
$240.98 P/Share
|
|
Feb 09
2024
|
Rachid Izzar Head of Global Product Strat. |
BUY
Exercise of conversion of derivative security
|
Direct |
1,515
+14.3%
|
-
|
|
Feb 09
2024
|
Robin Kramer Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
245
-4.44%
|
$58,800
$240.98 P/Share
|
|
Feb 09
2024
|
Robin Kramer Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
833
+13.11%
|
-
|
|
Feb 09
2024
|
Michael R Mcdonnell EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,431
-8.15%
|
$343,440
$240.98 P/Share
|
|
Feb 09
2024
|
Michael R Mcdonnell EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,257
+15.65%
|
-
|
|
Feb 09
2024
|
Nicole Murphy Head of Pharm Ops and Tech |
SELL
Payment of exercise price or tax liability
|
Direct |
761
-7.99%
|
$182,640
$240.98 P/Share
|
|
Feb 09
2024
|
Nicole Murphy Head of Pharm Ops and Tech |
BUY
Exercise of conversion of derivative security
|
Direct |
2,272
+19.25%
|
-
|
|
Feb 09
2024
|
Susan H Alexander EVP Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
938
-1.88%
|
$225,120
$240.98 P/Share
|
|
Feb 09
2024
|
Susan H Alexander EVP Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,575
+4.9%
|
-
|
|
Feb 08
2024
|
Ginger Gregory EVP, Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
498
-4.92%
|
$119,520
$240.3 P/Share
|
|
Feb 08
2024
|
Ginger Gregory EVP, Human Resources |
BUY
Exercise of conversion of derivative security
|
Direct |
1,635
+13.91%
|
-
|